Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Study did not meet the primary endpoints of overall survival (OS) in the full study population or in the leiomyosarcoma (LMS) sub-population; there was no difference in survival between the study arms for either population.
There were no new safety sign... Biopharmaceuticals, Oncology Eli Lilly, LARTRUVO, olaratumab, soft tissue sarcoma, leiomyosarcoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 18, 2019 Category: Pharmaceuticals Source Type: news
Trial Failure Still Yields Insights for Uterine Leiomyosarcoma
Experts weigh in on valuable findings that can be gleaned despite the fact that the phase III trial did not generate clinically meaningful results. (Source: CancerNetwork)
Source: CancerNetwork - January 10, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Report: Olympus study of next-gen power morcellator draws criticism
Olympus (TYO:7733) is receiving criticism after moving forward with plans to revitalize its powered morcellator devices, with a new 140-patient trial planned, according to a Philadelphia Inquirer report.
Power morcellators, which use a cutting tip to shred and remove uterine tissue, have been implicated in the spread of a lethal cancer that can masquerade undetected as benign fibroids. The devices designed to be used to remove benign uterine fibroids, but when used on malignant tissue, can spread cancerous cells throughout the abdomen.
Olympus won FDA 510(k) clearance for a next-generation laparoscopic PK morcellator, fea...
Source: Mass Device - August 14, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Oncology Source Type: news
MassDevice.com +5 | The top 5 medtech stories for June 13, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Vertos Medical raises $28m for Mild spine treatment
Vertos Medical said yesterday that it closed a $28 million financing round for its Mild treatment for lumbar spinal stenosis.
The round was led by new investor MVM Life Scienc...
Source: Mass Device - June 13, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Olympus settles power morcellator suit
An Olympus (TYO:7733) subsidiary agreed to settle a lawsuit filed over the power laparoscopic morcellator used in a gynecological surgery.
Plaintiffs Betty and Elvis Dobson alleged that the Olympus KS PlasmaSORD used in Betty’s 2010 hysterectomy spread myxoid leiomyosarcoma cells in her abdomen and pelvis. Power morcellators use small, rotating blades to break up large tissue masses into fragments and are commonly used to remove benign uterine fibroids in women. Although the FDA approved morcellators in 1995, it wasn’t until 2013 that the late Dr. Amy Reed exposed the risk after undergoing a hysterectomy at the...
Source: Mass Device - June 13, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Legal News Women's Health Olympus Source Type: news
Four presentations of skin conditions
The presentation, diagnosis and management of cutaneous infection with Mycobacterium chelonae, basal cell carcinoma, leiomyosarcoma and disseminated superficial actinic porokeratosis. (Source: GP Online Education)
Source: GP Online Education - June 13, 2017 Category: Primary Care Tags: 15.10 Skin Problems Source Type: news
Patient safety pioneer Dr. Amy Reed dies at 44
The physician who helped put an end to the 18-year gap between the FDA’s approval of laparoscopic power morcellators and the safety watchdog learning that the devices can spread malignant cancers in the abdomen, Dr. Amy Reed, died yesterday of leiomyosarcoma, according to news reports. She was 44.
Power morcellators use small, rotating blades to break up large tissue masses into fragments and are commonly used to remove benign uterine fibroids in women. But if the device is used on a patient with undetected cancer, it can strew cancerous cells throughout the abdomen. Although the FDA approved morcellators in 1995,...
Source: Mass Device - May 25, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Women's Health Source Type: news
My hysterectomy and cancer journey – Anya ’ s story
The post My hysterectomy and cancer journey – Anya’s story appeared first on Hysterectomy Association.
I had been suffering from heavy bleeding on and off since the birth of my second child in 2012 , medication and the contraceptive pill did nothing to ease the bleeding and I was referred to a gynaecologist, I initially saw a locum gynaecologist who persuaded me to have a Mirena coil fitted.
However that made matters matters worse and some six months later following several appointments with another gynaecologist, a hysteroscopy and scans it was discovered that coil had managed to lodge itself in my uterus and ...
Source: The Hysterectomy Association - March 24, 2017 Category: OBGYN Authors: Linda Tags: Your Stories cancer leiomyosarcoma Source Type: news
My hysterectomy and cancer journey – Anya ’ s story
I had been suffering from heavy bleeding on and off since the birth of my second child in 2012 , medication and the contraceptive pill did nothing to ease the bleeding and I was referred to a gynaecologist, I initially saw a locum gynaecologist who persuaded me to have a Mirena coil fitted.
However that made matters matters worse and some six months later following several appointments with another gynaecologist, a hysteroscopy and scans it was discovered that coil had managed to lodge itself in my uterus and that the small fibroid I had had for years had suddenly enlarged in size. My gynaecologist recommended I had a hyst...
Source: The Hysterectomy Association - March 24, 2017 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health cancer hysterectomy stories Source Type: news
My hysterectomy and cancer journey – Anya ’ s story
I had been suffering from heavy bleeding on and off since the birth of my second child in 2012 , medication and the contraceptive pill did nothing to ease the bleeding and I was referred to a gynaecologist, I initially saw a locum gynaecologist who persuaded me to have a Mirena coil fitted.
However that made matters matters worse and some six months later following several appointments with another gynaecologist, a hysteroscopy and scans it was discovered that coil had managed to lodge itself in my uterus and that the small fibroid I had had for years had suddenly enlarged in size. My gynaecologist recommended I had a hyst...
Source: The Hysterectomy Association - March 24, 2017 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health cancer hysterectomy stories Source Type: news
PI3K/mTOR inhibitors may be effective against some uterine sarcomas
The protein P-S6S240 may serve as an indicator of poor prognosis for patients with a hard-to-treat type of uterine sarcoma called leiomyosarcoma, and preclinical data suggest that patients whose tumors have this protein may respond to PI3K/mTOR inhibitors. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 23, 2017 Category: Science Source Type: news
PI3K/mTOR inhibitors may be effective against some uterine sarcomas
(American Association for Cancer Research) The protein P-S6S240 may serve as an indicator of poor prognosis for patients with a hard-to-treat type of uterine sarcoma called leiomyosarcoma, and preclinical data suggest that patients whose tumors have this protein may respond to PI3K/mTOR inhibitors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 23, 2017 Category: Cancer & Oncology Source Type: news
Aldoxorubicin Improves PFS in Some Relapsed/Refractory Sarcomas
Aldoxorubicin yielded significantly better progression-free survival over investigator ’s choice of various chemotherapy options in patients with relapsed or refractory leiomyosarcoma and liposarcoma, according to updated results of a phase III trial. (Source: CancerNetwork)
Source: CancerNetwork - December 30, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Sarcoma Source Type: news
Olympus wins FDA nod & launches new power morcellator with tissue capture
Olympus (TYO:7733) said today it won FDA 510(k) clearance for its next-gen laparoscopic PK morcellator with tissue containment designed as a laparoscopic surgery option to avoid open hysterectomy and myomectomy for uterine fibroid removal
The company’s newly launched morcellator includes the company’s PneumoLiner contained tissue extraction system.
“Contained tissue extraction is continually evolving. As surgeons, it is our duty to evaluate potential solutions to the surgical challenges we face in clinical practice. We are pleased that Olympus has taken the initiative to develop a unique and well tested ...
Source: Mass Device - November 16, 2016 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Business/Financial News Food & Drug Administration (FDA) Regulatory/Compliance Women's Health Olympus Source Type: news
